Bicocca Open Archive

Logo unimib boa
SENNI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.543
AS - Asia 22.763
EU - Europa 12.165
SA - Sud America 3.265
Continente sconosciuto - Info sul continente non disponibili 1.734
AF - Africa 457
OC - Oceania 38
Totale 65.965
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.619
SG - Singapore 7.235
VN - Vietnam 5.025
IT - Italia 4.765
HK - Hong Kong 3.992
CN - Cina 2.989
BR - Brasile 2.461
RU - Federazione Russa 2.319
CA - Canada 1.440
IE - Irlanda 1.346
BD - Bangladesh 1.217
DE - Germania 926
SE - Svezia 615
FR - Francia 582
IN - India 460
GB - Regno Unito 384
AR - Argentina 330
FI - Finlandia 254
ID - Indonesia 251
KR - Corea 240
MX - Messico 192
IQ - Iraq 189
JP - Giappone 164
UA - Ucraina 155
NL - Olanda 150
AT - Austria 147
TR - Turchia 137
EC - Ecuador 125
PK - Pakistan 120
ZA - Sudafrica 120
CO - Colombia 103
SA - Arabia Saudita 99
ES - Italia 97
PH - Filippine 95
PL - Polonia 84
MY - Malesia 83
VE - Venezuela 71
JM - Giamaica 64
UZ - Uzbekistan 59
MA - Marocco 58
TN - Tunisia 56
PY - Paraguay 54
CR - Costa Rica 52
BE - Belgio 48
CL - Cile 47
TH - Thailandia 45
AE - Emirati Arabi Uniti 41
JO - Giordania 41
EG - Egitto 38
KE - Kenya 36
ET - Etiopia 34
AU - Australia 30
NP - Nepal 30
HN - Honduras 29
NI - Nicaragua 29
RO - Romania 29
UY - Uruguay 29
DK - Danimarca 28
PE - Perù 27
DZ - Algeria 26
CH - Svizzera 25
IR - Iran 25
KZ - Kazakistan 25
TT - Trinidad e Tobago 25
HU - Ungheria 24
LT - Lituania 24
CZ - Repubblica Ceca 23
LB - Libano 22
PS - Palestinian Territory 22
GT - Guatemala 21
OM - Oman 19
PT - Portogallo 19
IL - Israele 18
NO - Norvegia 17
AZ - Azerbaigian 16
EE - Estonia 16
TW - Taiwan 16
RS - Serbia 15
SV - El Salvador 15
BO - Bolivia 13
NG - Nigeria 13
SY - Repubblica araba siriana 13
CI - Costa d'Avorio 11
KG - Kirghizistan 11
QA - Qatar 11
AO - Angola 10
GR - Grecia 10
PR - Porto Rico 10
SN - Senegal 10
DO - Repubblica Dominicana 9
LV - Lettonia 9
PA - Panama 9
AL - Albania 8
BG - Bulgaria 8
BH - Bahrain 8
KW - Kuwait 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
BW - Botswana 7
GE - Georgia 7
Totale 64.099
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.935
Singapore 3.893
Ashburn 2.707
San Jose 2.116
Ho Chi Minh City 1.574
Milan 1.397
Dublin 1.295
Hanoi 1.237
Toronto 1.122
New York 880
Chandler 807
Chicago 792
Council Bluffs 757
Princeton 747
Los Angeles 679
Santa Clara 624
Hefei 602
The Dalles 591
Ann Arbor 581
Frankfurt am Main 557
Rome 555
Dallas 486
Lauterbourg 430
Beijing 356
Lawrence 291
Fairfield 289
Moscow 289
Buffalo 275
Altamura 268
Seoul 224
São Paulo 217
Seattle 181
Helsinki 177
Boardman 164
Da Nang 160
Jakarta 157
Wilmington 155
Nuremberg 150
Figino 149
Houston 148
Andover 147
Haiphong 143
Phoenix 135
Shanghai 122
San Diego 116
Naples 114
Turin 111
Cambridge 109
Woodbridge 107
Tokyo 103
Washington 100
Brooklyn 96
Biên Hòa 92
Rio de Janeiro 92
Ha Long 91
Montreal 91
Quận Bình Thạnh 91
Ninh Bình 90
Atlanta 89
Denver 88
London 88
Orem 78
Can Tho 75
Columbus 75
Hải Dương 75
Baghdad 73
Vienna 71
Philadelphia 70
San Francisco 69
Guangzhou 68
Salt Lake City 68
Thái Nguyên 68
Munich 64
Bắc Ninh 59
Pune 59
Boston 57
Brasília 57
Bologna 56
Warsaw 56
Mexico City 54
Bắc Giang 53
Vũng Tàu 53
Lappeenranta 51
San Mateo 51
Charlotte 49
Miami 49
Tashkent 49
Elk Grove Village 47
Dhaka 46
Newark 46
Belo Horizonte 45
Johannesburg 45
Queens 45
Kuala Lumpur 44
Las Vegas 44
Brussels 43
Guayaquil 42
Biloxi 41
Istanbul 40
Quận Một 40
Totale 36.404
Salva come PNG Salva come JPEG
Nome #
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials 659
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial 592
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 559
Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction between Supine Versus Upright Exercise Hemodynamic Testing 536
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes 523
Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction 481
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: Results from an Italian multicenter study 467
Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study 466
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 462
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry 427
Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years 377
A matter of sex—persistent predictive value of MECKI score prognostic power in men and women with heart failure and reduced ejection fraction: a multicenter study 371
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials 358
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 358
Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study 358
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients 338
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure 335
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 321
Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study 313
Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study 311
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 309
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction 307
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization 303
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial 302
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction 297
Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study 292
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 288
Clonal hematopoiesis of indeterminate potential: implications for the cardiologists 282
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 277
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial 267
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 257
Evolocumab and clinical outcomes in patients with cardiovascular disease 255
Position paper ANMCO sull'utilizzo della terapia con sacubitril/valsartan nel paziente con scompenso cardiaco [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure] 253
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 249
Right ventricular reserve in cardiopulmonary disease: A simultaneous hemodynamic and three-dimensional echocardiographic study 248
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 248
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 247
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 240
Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation 235
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure 230
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis 227
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 226
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 226
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment 225
An uncommon and challenging finding regarding the tricuspid valve: Case report, clinical considerations, and practical management 225
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 218
Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects 218
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 213
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial 212
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 207
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF 204
QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance 204
The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique 203
Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure 203
Finerenone in Heart Failure with Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial 201
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 200
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial 196
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease 194
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus 194
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities 190
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC 190
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici] 188
Erratum: Heart failure at the crossroads: Moving beyond blaming stakeholders to targeting the heart (Eur J Heart Fail (2015) 17:8 (760-763) doi:10.1002/ejhf.315)) 188
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF 188
The chronic heart failure evolutions: Different fates and routes 187
Exercise Right Ventricular-Pulmonary Arterial Coupling and Functional Outcome in Patients Undergoing Surgery for Secondary Ischemic Mitral Regurgitation 182
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry 182
Emergency surgery of acute coronary insufficiency [La chirurgia d'urgenza nell'insufficienza coronarica acuta.] 182
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), with the special contribution of the Heart Failure Association (HFA) of the ESC 182
Finerenone and Atrial Fibrillation in Heart Failure A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial 179
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis 178
Prognostic Value of sST2 in Heart Failure 177
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens 177
A 57-year-old man with rapidly progressive pulmonary hypertension 175
Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial 173
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review 170
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 170
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19 166
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial 166
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction 165
S Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction 164
Heart failure with preserved ejection fraction: Update on diagnosis and therapy [Scompenso cardiaco con frazione di eiezione preservata: Update in tema di diagnosi e terapia] 162
Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study 161
The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels 160
The follow-up of patients undergoing percutaneous coronary intervention: Potential impact of the application of a clinical pathway-structured management on the hospital-community integration and modulated on the patient's clinical risk 159
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF 159
Assistenza ventricolare sinistra dopo correzione combinata di stenosi valvolare aortica e coartazione istmica 157
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 155
Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial 155
Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome 155
Vasopressors and inotropes in cardiogenic shock: Is there room for "adrenaline resuscitation"? 154
Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study 153
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 153
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study 152
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity 151
Bacterial Pericarditis due to Providencia stuartii An Atypical Case of Relapsing Pericarditis 150
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug 149
Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis 148
Sacubitril/valsartan, a new and effective treatment of heart failure with reduced ejection fraction [Sacubitril/valsartan, una nuova ed efficace terapia dello scompenso cardiaco a funzione sistolica ridotta] 148
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry 147
Totale 24.841
Salva come PNG Salva come JPEG
Categoria #
all - tutte 247.880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 247.880
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.721 0 0 0 45 88 27 28 49 41 63 1.676 704
2022/20233.988 640 1.090 282 272 208 769 54 195 273 42 95 68
2023/20243.637 68 105 98 138 590 1.004 689 92 333 95 38 387
2024/202512.162 466 1.221 441 471 1.283 473 1.104 347 1.518 1.639 946 2.253
2025/202632.457 4.379 3.430 1.888 2.627 2.724 1.395 3.931 1.451 2.079 2.286 2.509 3.758
2026/20279.659 1.621 2.064 4.378 1.596 0 0 0 0 0 0 0 0
Totale 65.965